| 4NZ2 | date | ![]() |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| authors | |||||||||||||||
| compound | source | ||||||||||||||
| symmetry |
| ||||||||||||||
| crystal cell |
| ||||||||||||||
| method | X-Ray Diffraction | resolution | |||||||||||||
| ligand | 2QJ, GOL, HEM, SO4 | enzyme |
| ||||||||||||
| Gene Ontology |
| ||||||||||||||
| Primary reference | Structure-based ligand design to overcome CYP inhibition in drug discovery projects., Branden G, Sjogren T, Schnecke V, Xue Y, Drug Discov Today. 2014 Jul;19(7):905-911. doi: 10.1016/j.drudis.2014.03.012., Epub 2014 Mar 16. PMID:24642031 | ||||||||||||||
| Data retrieval |
![]() |
| View 4NZ2 in 3D |
Proteopedia, because life has more than 2D. |
| Structure-derived information |
| Sequence-derived information |
|
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |